Genetown
Filter News
Found 92,485 articles
-
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
3/28/2024
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM) today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.
-
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
3/28/2024
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.
-
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
3/28/2024
Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET.
-
Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones
3/28/2024
SynDevRx, Inc., a pioneering clinical-stage biotechnology company based in Cambridge, Massachusetts, has achieved a significant milestone.
-
Harbour BioMed Reports Full Year 2023 Financial Results
3/28/2024
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual financial results of full year 2023.
-
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
3/28/2024
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.
-
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
3/28/2024
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
-
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
3/27/2024
TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.
-
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
3/27/2024
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel PARP/Tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its DRP® platform to identify and enroll only the patients most likely to derive clinical benefit.
-
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
3/27/2024
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.
-
Thermo Fisher Scientific Announces a New In-line Metrology Solution to Improve Battery Safety and Performance
3/27/2024
To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently.
-
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
3/27/2024
Pyxis Oncology, Inc. announced that it has completed the sale of its rights to royalties from the commercialization of Beovu® and another asset to Novartis for a one-time cash payment of $8 million.
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
3/27/2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.
-
Merrimack Receives $225 Million Milestone Payment from Ipsen
3/27/2024
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
-
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
3/27/2024
Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
3/27/2024
Moderna, Inc. announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline.
-
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
3/27/2024
Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.
-
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
3/27/2024
TellBio, Inc. announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - March 27, 2024
3/27/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.
-
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
3/27/2024
BiomX Inc. announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update.